Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by First Hawaiian Bank

First Hawaiian Bank lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 2,624 shares of the biopharmaceutical company’s stock after selling 36 shares during the period. First Hawaiian Bank’s holdings in Regeneron Pharmaceuticals were worth $2,758,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Atria Investments Inc lifted its holdings in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after buying an additional 941 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after purchasing an additional 5,495 shares during the last quarter. Tidal Investments LLC increased its position in shares of Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $1,011,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $1,232,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,074 shares of company stock worth $64,546,123. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN traded down $10.91 during midday trading on Monday, hitting $1,071.28. The company had a trading volume of 611,139 shares, compared to its average volume of 471,453. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. The company has a market capitalization of $118.04 billion, a PE ratio of 31.77, a P/E/G ratio of 2.34 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $765.28 and a twelve month high of $1,115.00. The firm’s 50-day simple moving average is $1,043.43 and its 200-day simple moving average is $983.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on REGN. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday. Piper Sandler boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday. Barclays boosted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday. Finally, Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,097.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.